NO20072529L - Cytotoksisk utforming for kombinasjonsbehandling - Google Patents

Cytotoksisk utforming for kombinasjonsbehandling

Info

Publication number
NO20072529L
NO20072529L NO20072529A NO20072529A NO20072529L NO 20072529 L NO20072529 L NO 20072529L NO 20072529 A NO20072529 A NO 20072529A NO 20072529 A NO20072529 A NO 20072529A NO 20072529 L NO20072529 L NO 20072529L
Authority
NO
Norway
Prior art keywords
cytotoxic
design
combination therapy
methods
liposomes
Prior art date
Application number
NO20072529A
Other languages
English (en)
Norwegian (no)
Inventor
Roy Larsen
Thora Johanna Jonasdottir
Original Assignee
Algeta Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algeta Asa filed Critical Algeta Asa
Publication of NO20072529L publication Critical patent/NO20072529L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20072529A 2004-10-22 2007-05-18 Cytotoksisk utforming for kombinasjonsbehandling NO20072529L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0423565.1A GB0423565D0 (en) 2004-10-22 2004-10-22 Formulation
PCT/GB2005/004074 WO2006043083A2 (en) 2004-10-22 2005-10-21 Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy

Publications (1)

Publication Number Publication Date
NO20072529L true NO20072529L (no) 2007-05-18

Family

ID=33485085

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072529A NO20072529L (no) 2004-10-22 2007-05-18 Cytotoksisk utforming for kombinasjonsbehandling

Country Status (17)

Country Link
US (1) US20080193374A1 (pt)
EP (1) EP1812115B1 (pt)
JP (1) JP5615483B2 (pt)
KR (2) KR20070108851A (pt)
CN (1) CN101060886A (pt)
AU (1) AU2005297082B2 (pt)
BR (1) BRPI0517006A (pt)
CA (1) CA2583367C (pt)
EA (1) EA011715B1 (pt)
ES (1) ES2424844T3 (pt)
GB (1) GB0423565D0 (pt)
IL (1) IL182634A (pt)
MX (1) MX2007004542A (pt)
NO (1) NO20072529L (pt)
NZ (1) NZ582713A (pt)
WO (1) WO2006043083A2 (pt)
ZA (1) ZA200704035B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294496T3 (es) 2003-04-30 2008-04-01 Ramot At Tel Aviv University Ltd. Metodo y dispositivo para radioterapia.
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
AU2010272957B2 (en) * 2009-07-17 2016-03-03 Rigshospitalet Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
AU2011344865B2 (en) 2010-12-14 2017-03-09 Rigshospitalet Entrapment of radionuclides in nanoparticle compositions
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
WO2014039874A2 (en) * 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
EP2934545A1 (en) * 2012-12-19 2015-10-28 Bayer Pharma Aktiengesellschaft Combination comprising radium-223 for the treatment of cancer
WO2014099056A2 (en) 2012-12-20 2014-06-26 Carnegie Mellon University Methods and materials for reducing organ transplant rejection or ischemic/reperfusion injury in a subject
US10792366B2 (en) 2015-02-19 2020-10-06 Carnegie Mellon University Methods to reduce toxicities and to improve bioavailabilities of nanodrugs
DK3261681T3 (da) * 2015-02-26 2020-04-27 Sciencons AS Radiofarmaceutiske opløsninger med fordelagtige egenskaber
US9433690B1 (en) * 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
SI3111959T1 (en) * 2015-07-03 2018-04-30 Oncoinvent As Radiotherapeutic particles and suspensions
AU2018265386B2 (en) 2017-05-11 2020-07-23 Alpha Tau Medical Ltd. Polymer coatings for brachytherapy devices
MX2020009940A (es) 2018-04-02 2020-10-16 Alpha Tau Medical Ltd Liberacion controlada de radionucleidos.
WO2022058338A1 (en) * 2020-09-15 2022-03-24 Oncoinvent As Preparations of radium-224 and progenies for use in radionuclide therapy in combination with dna repair inhibitors
US11857803B2 (en) 2020-12-16 2024-01-02 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy with enhanced beta treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
WO2001097859A1 (en) * 2000-06-16 2001-12-27 Sloan-Kettering Institute For Cancer Research Liposomal encapsulation of chelated actinium-225 and uses thereof
US20040166060A1 (en) * 2000-06-16 2004-08-26 Sloan Kettering Institute For Cancer Research Liposomal encapsulation of alpha particle emittors and uses thereof
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
US7718160B2 (en) * 2002-07-02 2010-05-18 The Board Of Regents Of The University Of Texas System Radiolabeled compounds and liposomes and their method of making and using same
US7254229B2 (en) * 2003-03-07 2007-08-07 Legerity, Inc. Method and apparatus for an active impedance feedback
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US20060228297A1 (en) * 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease

Also Published As

Publication number Publication date
EA011715B1 (ru) 2009-04-28
JP2008517049A (ja) 2008-05-22
WO2006043083A8 (en) 2007-09-27
CA2583367A1 (en) 2006-04-27
IL182634A (en) 2016-03-31
AU2005297082B2 (en) 2011-11-17
US20080193374A1 (en) 2008-08-14
JP5615483B2 (ja) 2014-10-29
WO2006043083A3 (en) 2007-01-04
ES2424844T3 (es) 2013-10-09
MX2007004542A (es) 2007-08-17
EP1812115B1 (en) 2013-05-15
WO2006043083A2 (en) 2006-04-27
BRPI0517006A (pt) 2008-09-30
ZA200704035B (en) 2008-08-27
AU2005297082A1 (en) 2006-04-27
CA2583367C (en) 2014-09-16
EA200700686A1 (ru) 2007-10-26
IL182634A0 (en) 2007-07-24
EP1812115A2 (en) 2007-08-01
KR20130019029A (ko) 2013-02-25
NZ582713A (en) 2012-06-29
CN101060886A (zh) 2007-10-24
GB0423565D0 (en) 2004-11-24
KR20070108851A (ko) 2007-11-13

Similar Documents

Publication Publication Date Title
NO20072529L (no) Cytotoksisk utforming for kombinasjonsbehandling
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
MX339142B (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
TW200730502A (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
MX2009011444A (es) Titulacion del tapentadol.
IL206563A (en) A preparation or drug containing a suspension of blood cells that contain asparaginase for use in the treatment of pancreatic cancer
TW200626159A (en) Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor
NO20065936L (no) Sulfonyletylfosfordiamidater for anvendelse ved behandling av cancer.
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
MXPA03009849A (es) Uso de azitromicina para la fabricacion de un medicamento para el tratamiento de enfermedades inflamatorias no infecciosas.
UA90504C2 (ru) Лекарственное средство для лечения заболеваний дыхательных путей
CY1113488T1 (el) Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας
TW200719903A (en) Compositions for the treatment of neoplasms
TW200719899A (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
WO2007080116A3 (en) Use of cns penetrating anticancer compounds for the treatment of protozan diseases
TW200634002A (en) Chemical compounds
HUP0302296A2 (hu) Eljárás és készítmény rák kezelésére, apoptosist indukáló kemoterápiás szerek adagolásával
TW200716618A (en) Chemical compounds
TW200720239A (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application